Literature DB >> 20519954

Small RNA-directed transcriptional control: new insights into mechanisms and therapeutic applications.

Chiara Pastori1, Marco Magistri, Sara Napoli, Giuseppina M Carbone, Carlo V Catapano.   

Abstract

The discovery of RNA interference (RNAi) has opened new avenues in biology and medicine. In addition to post-transcriptional gene silencing, new findings are expanding the range of action of small duplex RNAs and broadening the spectrum of the potential applications of RNAi-based therapeutics. In recent years a complex and heterogeneous network of non-protein coding RNAs (ncRNAs) with potential regulatory functions has come into the spotlight providing an unexpected perspective on the mechanisms of transcriptional and epigenetic control of gene expression in human cells. The spread and complexity of these RNA-based transcriptional regulatory networks are still to be explored. However, they are likely to be important mechanisms controlling gene expression in human cells. As we will learn more about these processes, endogenous small RNAs and ncRNAs participating in these transcriptional regulatory networks might become valuable targets to modulate expression of genes involved in human diseases. Thus, understanding these basic processes of gene regulation might be translated in the near future into innovative therapeutic strategies to treat human diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20519954     DOI: 10.4161/cc.9.12.12049

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  6 in total

1.  Antisense RNA controls LRP1 Sense transcript expression through interaction with a chromatin-associated protein, HMGB2.

Authors:  Yasunari Yamanaka; Mohammad Ali Faghihi; Marco Magistri; Oscar Alvarez-Garcia; Martin Lotz; Claes Wahlestedt
Journal:  Cell Rep       Date:  2015-04-30       Impact factor: 9.423

2.  Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter.

Authors:  Masayuki Matsui; Fuminori Sakurai; Sayda Elbashir; Donald J Foster; Muthiah Manoharan; David R Corey
Journal:  Chem Biol       Date:  2010-12-22

3.  CANEapp: a user-friendly application for automated next generation transcriptomic data analysis.

Authors:  Dmitry Velmeshev; Patrick Lally; Marco Magistri; Mohammad Ali Faghihi
Journal:  BMC Genomics       Date:  2016-01-13       Impact factor: 3.969

4.  A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers.

Authors:  Giuseppina Pisignano; Sara Napoli; Marco Magistri; Sarah N Mapelli; Chiara Pastori; Stefano Di Marco; Gianluca Civenni; Domenico Albino; Claudia Enriquez; Sara Allegrini; Abhishek Mitra; Gioacchino D'Ambrosio; Maurizia Mello-Grand; Giovanna Chiorino; Ramon Garcia-Escudero; Gabriele Varani; Giuseppina M Carbone; Carlo V Catapano
Journal:  Nat Commun       Date:  2017-05-30       Impact factor: 14.919

5.  Transcriptomics Profiling of Alzheimer's Disease Reveal Neurovascular Defects, Altered Amyloid-β Homeostasis, and Deregulated Expression of Long Noncoding RNAs.

Authors:  Marco Magistri; Dmitry Velmeshev; Madina Makhmutova; Mohammad Ali Faghihi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

6.  The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease.

Authors:  Marco Magistri; Dmitry Velmeshev; Madina Makhmutova; Prutha Patel; Gregory C Sartor; Claude-Henry Volmar; Claes Wahlestedt; Mohammad Ali Faghihi
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.